0000904454-14-000398.txt : 20140501
0000904454-14-000398.hdr.sgml : 20140501
20140501194347
ACCESSION NUMBER: 0000904454-14-000398
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140501
FILED AS OF DATE: 20140501
DATE AS OF CHANGE: 20140501
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
BUSINESS PHONE: 617-513-9882
MAIL ADDRESS:
STREET 1: 15 NEW ENGLAND EXECUTIVE PARK
CITY: BURLINGTON
STATE: MA
ZIP: 01803
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON & JOHNSON DEVELOPMENT CORP ET AL
CENTRAL INDEX KEY: 0000924020
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 14806603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON & JOHNSON
CENTRAL INDEX KEY: 0000200406
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1212
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 14806604
BUSINESS ADDRESS:
STREET 1: ONE JOHNSON & JOHNSON PLZ
CITY: NEW BRUNSWICK
STATE: NJ
ZIP: 08933
BUSINESS PHONE: 732-524-2455
MAIL ADDRESS:
STREET 1: ONE JOHNSON & JOHNSON PLZ
CITY: NEW BRUNSWICK
STATE: NJ
ZIP: 08933
3
1
edgar.xml
PRIMARY DOCUMENT
X0206
3
2014-05-01
0
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0000200406
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933
0
0
1
0
0000924020
JOHNSON & JOHNSON DEVELOPMENT CORP ET AL
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933
0
0
1
0
Series A Preferred Stock
Common Stock
915366
I
By Johnson & Johnson Development Corporation
Non-Voting Series A Preferred Stock
Common Stock
247694
I
By Johnson & Johnson Development Corporation
Series B Preferred Stock
Common Stock
427591
I
By Johnson & Johnson Development Corporation
Non-Voting Series B Preferred Stock
Common Stock
133827
I
By Johnson & Johnson Development Corporation
Series B Preferred Stock Warrant (Right to Buy)
2017-12-20
Common Stock
36345
I
By Johnson & Johnson Development Corporation
Series B Preferred Stock Warrant (Right to Buy)
2018-08-14
Common Stock
36345
I
By Johnson & Johnson Development Corporation
The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Development Corporation, a wholly-owned subsidiary of the designated Reporting Person.
All outstanding shares of the Issuer's preferred stock will automatically convert into Common Stock immediately following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series A Preferred Stock and Non-Voting Series A Preferred Stock will convert into shares of Common Stock on a 2.3726-for-1 basis and each share of Series B Preferred Stock and Non-Voting Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis.
All outstanding warrants will be net exercised for shares of the Issuer's Series B Preferred Stock and subsequently will automatically convert into Common Stock following declaration of effectiveness of the Issuer's Registration Statement for no additional consideration. Each share of Series B Preferred Stock will automatically convert into shares of Common Stock on a 1-for-1 basis.
Douglas Chia, Secretary of Johnson & Johnson
2014-05-01
Steven M. Rosenberg, Secretary of Johnson & Johnson Development Corporation
2014-05-01